Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07491445 Albumin-Bound Paclitaxel Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07491445 clinical trial report covering Albumin-Bound Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07489755 TGRX-678 Chronic phase chronic myeloid leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07489755 clinical trial report covering TGRX-678, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07489495 Belzutifan Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07489495 clinical trial report covering Belzutifan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07490496 Ropivacaine Hydrochloride Bunion Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07490496 clinical trial report covering Ropivacaine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07492875 Nogapendekin alfa inbakicept-pmln Community Acquired Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07492875 clinical trial report covering Nogapendekin alfa inbakicept-pmln, Phase 3, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07493057 Bofanglutide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07493057 clinical trial report covering Bofanglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07492641 Letrozole Hormone receptor positive HER2 negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07492641 clinical trial report covering Letrozole, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07493109 Chidamide Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07493109 clinical trial report covering Chidamide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07493304 Cenvacibart Basal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07493304 clinical trial report covering Cenvacibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260414 Interferon alpha-2b(Anhui Anke Biotechnology) Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260414 clinical trial report covering Interferon alpha-2b(Anhui Anke Biotechnology), Phase 3, endpoints, sponsor, geography, readout timing and develo
Latest Hotspot
8 min read
JPRN-jRCT2071250151 Etoposide Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
JPRN-jRCT2071250151 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ISRCTN39379437 Guselkumab Colonic Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
ISRCTN39379437 clinical trial report covering Guselkumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.